140 related articles for article (PubMed ID: 9815912)
1. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder.
Allard P; Fradet Y; Têtu B; Bernard P
Clin Cancer Res; 1995 Oct; 1(10):1195-202. PubMed ID: 9815912
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal antibodies against transitional cell carcinoma assay tumor associated antigens in different grades bladder cancer patients].
Zhang H; Zhao Z; Sun H
Zhonghua Wai Ke Za Zhi; 1996 Sep; 34(9):560-2. PubMed ID: 9594163
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
4. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
6. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
7. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups.
Millán-Rodríguez F; Chéchile-Toniolo G; Salvador-Bayarri J; Huguet-Pérez J; Vicente-Rodríguez J
J Urol; 2000 Oct; 164(4):1183-7. PubMed ID: 10992362
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer.
Tetu B; Fradet Y; Allard P; Veilleux C; Roberge N; Bernard P
J Urol; 1996 May; 155(5):1784-8. PubMed ID: 8627884
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
10. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.
Ayari C; LaRue H; Hovington H; Caron A; Bergeron A; Têtu B; Fradet V; Fradet Y
Hum Pathol; 2013 Aug; 44(8):1630-7. PubMed ID: 23574787
[TBL] [Abstract][Full Text] [Related]
11. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
12. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
13. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
[TBL] [Abstract][Full Text] [Related]
14. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
15. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
16. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
18. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
Guney S; Guney N; Canogullari Z; Ergenekon E
Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
[TBL] [Abstract][Full Text] [Related]
19. [Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].
Werner W; Smesny S; Schubert J
Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):519-27. PubMed ID: 10996943
[TBL] [Abstract][Full Text] [Related]
20. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
